Literature DB >> 9865734

Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.

Q Wang1, W T Beck.   

Abstract

Multidrug resistance is a major obstacle to the success of cancer chemotherapy. The multidrug resistance-associated protein (MRP) has been shown to confer multidrug resistance. To study MRP gene expression at the transcriptional level, we have fused the MRP gene promoter with the luciferase reporter gene and studied its regulation. Cotransfection of MRP promoter constructs with p53 expression plasmids in p53-null human H1299 and mouse (10)1 cells demonstrated that the wild-type (wt) p53 markedly suppressed MRP promoter activity, whereas mutant p53 had little inhibitory effect. Transfections using 5' deletion mutant constructs of the MRP promoter showed that inhibition of the promoter activity by wt p53 mainly resided in the region from -91 to +103 bp, where several Sp1 transcription factor binding sites are localized. Cotransfection of the MRP promoter into Drosophila SL2 cells with an Sp1 expression vector increased the promoter activity in a dose-related manner up to approximately 200-fold. The stimulation of MRP promoter activity by Sp1 was attenuated by the cotransfection of a wt p53-expression plasmid. Furthermore, we have determined that endogenous MRP mRNA levels were down-regulated by restoration of wt p53-expression in a human lung cancer cell line. The relevance of MRP regulation in drug resistance was studied in a drug-resistant cell line, CEM/VM-1-5, that is approximately 140-fold more resistant to the epipodophyllotoxin, teniposide (VM-26), than the parental CEM cells. CEM/VM-1-5 cells express a much higher amount of MRP mRNA and protein than CEM cells, indicating that the resistant phenotype is at least partly due to increased MRP production. Transient transfection of the promoter constructs revealed that CEM/VM-1-5 cells had higher (7-fold) MRP promoter activity than CEM cells. Cotransfection of a wt p53-expression plasmid caused a reduction of MRP promoter activity in both CEM and CEM/VM-1-5 cells, but the inhibition was more than double in CEM/VM-1-5 cells compared with CEM cells. Our results demonstrated that wt p53 acts as a negative regulator of MRP gene transcription, at least in part by diminishing the effect of a powerful transcription activator Sp1. Therefore, a loss of wt p53 function and/or an increase in Sp1 activity in tumor cells could contribute to an up-regulation of the MRP gene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9865734

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Modulation of MDR/MRP by wild-type and mutant p53.

Authors:  O Bähr; W Wick; M Weller
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells.

Authors:  Sungpil Cho; Meiling Lu; Xiaolong He; Pui-Lai Rachel Ee; Uppoor Bhat; Erasmus Schneider; Lucio Miele; William T Beck
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 3.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

Review 4.  Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1).

Authors:  Eva Bakos; László Homolya
Journal:  Pflugers Arch       Date:  2006-12-23       Impact factor: 3.657

5.  Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells.

Authors:  G F Sullivan; J M Yang; A Vassil; J Yang; J Bash-Babula; W N Hait
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 6.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

7.  Expression of multidrug-associated protein, P-glycoprotein, P53 and Bcl-2 proteins in bladder cancer and clinical implication.

Authors:  Z Chen; Y Zhang; X Zhang; G Du; W Yang; Z Hu; J Li; Y Zhang
Journal:  J Tongji Med Univ       Date:  2001

8.  Differential expression levels of MRP1, MRP4, and MRP5 in response to human immunodeficiency virus infection in human macrophages.

Authors:  Sylvie Jorajuria; Nathalie Dereuddre-Bosquet; Karen Naissant-Storck; Dominique Dormont; Pascal Clayette
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 9.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

Review 10.  The individualization of cancer therapy: the unexpected role of p53.

Authors:  William N Hait; Jin-Ming Yang
Journal:  Trans Am Clin Climatol Assoc       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.